Main Article Content



Glioblastoma is considered one of the most aggressive malignant brain tumors, which has an extremely unfavorable prognosis and low patient survival. The low sensitivity to standard multimodal therapy is explained by the heterogeneity of the tumor cell pool and the presence of glioblastoma stem-like cells in the tumor. In recent years, much attention has been paid to the identification and study of molecular genetic disorders of glioblastoma. The most significant of them are the IDH1 gene mutation and the MGMT methylation status. Currently, the gold standard of treatment is the use of neuronavigation and intraoperative tumor fluorescence in surgery, these methods allow the most accurate and complete removal of the tumor. In this article, we will consider the pathogenesis, experimental technologies and modern methods of treating this disease.


Download data is not yet available.

Article Details

How to Cite
BON L.I., & LYCHKOVSKAYA M.A. (2022). GLIOBLASTOMA. ASPECTS OF PATHOGENESIS AND THERAPEUTIC APPROACHES. Innovat International Journal Of Medical & Pharmaceutical Sciences, 7(5), 1–6. Retrieved from
Review Article(s)


Tabatabai G, Weller M. Glioblastoma stem cells. Cell Tissue Res. 2011;343(3):459-65. doi: 10.1007/s00441-010-1123-0, PMID 21253762.

Int J Mol Sci. (2021) Deciphering the Role of Autophagy in Treatment of Resistance Mechanisms in Glioblastoma Imran Khan, Baig MH, Mahfooz S, Rahim M:1318.

Zottel A, Jovčevska I, Šamec Neja, Komel R. Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review. Crit Rev Oncol Hematol. 2021;160:103283. doi: 10.1016/j.critrevonc.2021.103283, PMID 33667657.

Di Nunno V, Franceschi E, Gatto L, Bartolini S. Future Oncol. Predictive Markers Immune Resp Glioblastoma Hopes Facts. 2020;15:1053-63.

Yan Chengrui, Kong X, Gong S, Liu F, Yuanli Zhao. Recent advances of the regulation roles of microRNA in glioblastoma. Int J Clin Oncol. 2020;7:1215-22.

Chavda V, Patel V, Yadav D, Shah JSC, Patel S, Jin JO. Therapeutics and research related to glioblastoma: advancements and future targets. Curr Drug Metab. 2020;21(3):186-98. doi: 10.2174/1389200221666200408083950, PMID 322688637. Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019;393(10172):678-88. doi: 10.1016/S0140-6736(18)31791-4, PMID 30782343.

M Touat, A Idbaih , M Sanson Ann Oncol (2017) Glioblastoma targeted therapy: updated approaches from recent biological insights 7:1457-1472.

Qiang Yang, Yanghao Zhou, Jin Chen, Ning Huang Int J Nanomedicine (2021) Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound 16:185-199.

Chibawanye I Ene, Juan Fueyo, Frederick F Lang Neurosurg Focus (2021) Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerations 2:1-6.

Lisa Feldman, Christine Brown, Behnam Badie Neurosurgery (2021) Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment 6:1056-1064.

Banafshe Abadi, Meysam Ahmadi-Zeidabadi, Luciana Dini, Cristian Vergallo Hematol Oncol Stem Cell Ther. (2021) Stem cell-based therapy treating glioblastoma multiforme 1:1-15.

Antonio Omuro, Lisa M DeAngelis JAMA (2013) Glioblastoma and other malignant gliomas: a clinical review 17:1842-50.

14 Marike L Broekman, Sybren L N Maas, Erik R Abels, Thorsten R Mempel Nat Rev Neurol. (2018) Multidimensional communication in the microenvirons of glioblastoma 8:482-495.

Anshika Goenka, Deanna Tiek, Xiao Song, Tianzhi Huang, Bo Hu Cells (2021) The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma 3:484.

16 R E Kast Ann Pharm (2021) Adding high-dose celecoxib to increase effectiveness of standard glioblastoma chemoirradiation 5:481-488.

Jaspar Witteler, Steven E Schild, Dirk Rades In Vivo (2021) Palliative Radiotherapy of Primary Glioblastoma 1:483-487.

Shreeja Datta, Ritika Luthra, Navneeta Bharadvaja Anticancer Agents Med Che (2022) Medicinal Plants for Glioblastoma Treatment 13:2367-2384.

Alipi Bonm, Santosh Kesari Cancer J (2021) DNA Damage Response in Glioblastoma: Mechanism for Treatment Resistance and Emerging Therapeutic Strategie 5:379-385.

Shubham Semwal, Rabah Boukherroub, Savvas N Savvide, Julie Bouckaert Curr Pharm Des (2021) Natural Antibodies: Protecting Role of IgM in Glioblastoma and Brain Tumours 45:4515-4529.

21 Liver Metastases Ghulam Ghous, Douglas Miller, Donald Doll, Tolga Tuncer Oncology (Williston Park) (2021) A Rare Case of Glioblastoma With Extensive 11:733-740.

Kiran Aftab, Faiqa Binte Aamir, Saad Mallick, Fatima Mubarak J Neurooncol (2022) Radiomics for precision medicine in glioblastoma 2:217-231.

Ramazan Uyar Pathol Res Pract (2022) Glioblastoma microenvironment: The stromal interactions 232:15-33.

I K Osinov, V V Kostjuchenko, G L Kobyakov, A S Belyashova Zh Vopr Neirokhir Im N N Burdenko (2021) Radiosurgery for recurrent glioblastoma 6:76-82.

Ding Fang Chuang, Xuling Lin Curr Oncol Rep (2019) Targeted Therapies for the Treatment of Glioblastoma in Adults 7:61.

Ikenna I Ogbu BMJ (2021) Glioblastoma: intraoperative monitoring and tumour classification 274:374.

Kanawat Wiwatchaitawee, Juliana C Quarterman, Sean M Geary, Aliasger K Salem AAPS PharmSciTech (2021) Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems 2:71.

Michael A Vogelbaum Neurosurg Clin N Am (2021) Surgical Management of Glioblastoma: More Than Just Diagnosis and Decompression 1:13-14.

Kumail Khandwala, Fatima Mubarak, Khurram Minhas Neuroradiol J (2021) The many faces of glioblastoma: Pictorial review of atypical imaging features 1:33-41.

Elio Mikhael, Hampig Raphaël Kourie Biomark Med (2021) Targeting glioblastoma: from dream to reality 6:385-388.31. Maya A Dymova, Elena V Kuligina, Vladimir A Richter Int J Mol Sci (2021) Molecular Mechanisms of Drug Resistance in Glioblastoma 12:6385.

Yuan Zhou, Weijian Wu, Hongye Bi, Dayong Yang Cancer Lett (2020) Glioblastoma precision therapy: From the bench to the clinic 475:79-91.

Axis Jinyang Hu, Qungen Xiao, Minhai Dong, Dongsheng Guo Front Immunol (2020) Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα 11:593219.

Ainhoa Hernández, Marta Domènech, Ana M Muñoz-Mármol, Cristina Carrato Cells (2021) Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment 12:3529.

D H Martin, E Bianchi, S Ben Mustapha, P Frères Rev Med Liege (2021) Glioblastoma 76:419-424.

Fadi Jacob, Ryan D Salinas, Daniel Y Zhang, Phuong T T Nguyen Cell (2020) A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity 1:188-204.

Ryan C Gimple, Shruti Bhargava, Deobrat Dixit, Jeremy N Rich Genes Dev (2019) Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer 6:591-609.38. Ruichong Ma, Martin J B Taphoorn, Puneet Plaha J Neurol Neurosurg Psychiatry (2021) Advances in the management of glioblastoma 10:1103-1111.

Patrick Y Wen, Michael Weller, Eudocia Quant Lee, Brian M Alexander Neuro Oncol (2020) Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions 8:1073-1113.

Alexander Ou, W K Alfred Yung, Nazanin Majd Int J Mol Sci (2020) Molecular Mechanisms of Treatment Resistance in Glioblastoma 1:351.

Emilie Le Rhun, Matthias Preusser, Patrick Roth, David A Reardon Cancer Treat Rev (2019) Molecular targeted therapy of glioblastoma 80:101896.

Chris McKinnon, Meera Nandhabalan, Scott A Murray, Puneet Plaha BMJ (2021) Glioblastoma: clinical presentation, diagnosis, and management 374:1560.

Tamara T Lah, Metka Novak, Barbara Breznik Semin Cancer Biol (2020) Brain malignancies: Glioblastoma and brain metastases 60:262-273.